SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Henry Niman who wrote (29287)9/19/1999 9:47:00 AM
From: Arthur Radley  Read Replies (1) | Respond to of 32384
 
Happened to find my annual report last night and was reviewing the projections for 1999. As for NDA's planned, I see the following:
1) Targretin capsules
2) Targretin gel
3) Panretin capsules
4) Elan filing for Morphelan

Report also indicates that Cytel would report on Cylexin that is in Phase III testing. Did I miss an update on this drug or has anything happened to move this drug forward in the process of filing an NDA?

Considering we only have on 3 1/2 months to go in 1999, if they meet the projections with these 4 drugs....the next few weeks should be very interesting.



To: Henry Niman who wrote (29287)9/20/1999 11:24:00 PM
From: aknahow  Read Replies (1) | Respond to of 32384
 
Man, (biochemist), bites dog again, gets $6 million, returns about 10% and agrees to not bite for 3 years. At that point he will be eligible for new federal grants and can do whatever, he has not admitted to doing.

There are big incentives to falsify research. Bet it's done much more often than anyone thinks.

sciam.com

If the FDA concentrated on safety only, they would have a better chance a detecting fraud.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News